CA-ENEVATE
14.1.2020 12:02:06 CET | Business Wire | Press release
Enevate , a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology capable of extreme fast charging for electric vehicles (EVs), announced its new 4th generation technology optimized for high volume commercialization and manufacturing at gigafactory scale. Enevate is providing a solution to a difficult problem for automotive OEMs and EV battery manufacturers – providing extreme fast charging with high energy density and at lower material cost than conventional Li-ion batteries, while being compatible with existing battery fabrication facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005035/en/
The new XFC-Energy™ technology achieves 5-minute charging to 75 percent capacity with 800 Wh/L cell energy density. Today’s conventional large-format Li-ion EV cells are at 500-600 Wh/L and typically take over 1 hour to charge.
“Mass EV adoption by consumers and fleet owners will depend to a large degree on advanced battery technology that will remove current barriers to entry such as long charging times and limited range,” said Christian Noske , Chairman of Alliance Ventures (Renault-Nissan-Mitsubishi). “Enevate is a key enabler for electric vehicles that are affordable, easy and quick to charge, and clean.”
Dr. John Goodenough , a recipient of the 2019 Nobel Prize in chemistry for groundbreaking work in the development of lithium-ion batteries and who has served on Enevate’s Advisory Board since 2010, added: “I salute the Enevate team for reaching this next important step in fulfilling the company’s mission to develop and commercialize innovative battery technologies to accelerate the adoption of electrified mobility.”
Enevate’s 4th generation XFC-Energy technology stands to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
Enevate’s 4th generation is the latest result of over 74 million hours of battery cell testing by Enevate’s scientists, 1 million meters of electrodes produced in the company’s R&D pilot line, and 2 billion test datapoints.
Enevate Founder and Chief Technology Officer Dr. Benjamin Park noted that Enevate’s XFC-Energy technology has been designed for large-format pouch, prismatic and cylindrical EV cells, utilizing its pure silicon anode paired with nickel-rich NCA, NCM and NCMA advanced cathodes.
“Enevate’s extreme fast charge technology enables a future where gas stations become drive-through EV charging stations – a win-win for consumers and the environment as electric vehicles replace those using gasoline,” Dr. Park said. “Enevate’s technology will help close the usability gap between today’s EVs and gas cars.”
Dr. Park will be discussing Enevate’s technology on January 15 at the Advanced Automotive Battery Conference in Weisbaden, Germany, in a presentation titled “Charging Ahead: Commercializing Fast-Charge Si-Dominant Li-ion Cells for EVs.”
XFC-Energy Technology Technical Details
- Cell technology scalable for large-format pouch, prismatic and cylindrical EV cells suitable for various battery module and pack architectures. Achieves 800 Wh/L and 340 Wh/kg in large-format EV cells.
- Pure silicon-dominant anode technology tunable with 10-60µm thickness and 1000-2000mAh/g that can be paired with NCA, NCM811, NCMA, low-cobalt, or other advanced cathode technologies.
- Continuous roll-to-roll anode manufacturing processes designed and capable of achieving over 80 meters per minute electrode production, over 10 GWh per electrode production line, with pure silicon anode rolls greater than 1 meter wide and longer than 5 kilometers in length sufficient for high volume gigafactory production, among other features.
- Lower anode material cost (dollar per kWh) than conventional and synthetic graphite.
- Transformative performance improvement, with five-minute charge to 75 percent of battery capacity, and, when paired with a high-nickel cathode, capable of over 1000 cycles using an EV drive cycle test and operation at -20˚C and below temperatures.
- Bottom line: Five-minute extreme fast charging, high energy density, low temperature operation, low cost and superior safety.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. With a portfolio of more than 200 patents issued and in process, Enevate’s pioneering advancements in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional Li-ion batteries.
Enevate’s vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company has raised over $110 million from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital and Bangchak. Enevate®, the Enevate logo, XFC-Energy™, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
